News

NewAmsterdam Pharma's Upcoming Investor Conference Highlights

NewAmsterdam Pharma's Upcoming Investor Conference Highlights

NewAmsterdam Pharma's Upcoming Investor Conference Schedule

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), a pioneering force in the biopharmaceutical landscape, is gearing up for an exciting lineup of investor conferences in June. Recognized for developing oral non-statin medicines aimed at significantly improving the lives of patients at risk for cardiovascular disease (CVD), NewAmsterdam continues to push forward with their mission even as they prepare for these crucial events. The company's innovative approach looks to meet the needs of individuals with elevated low-density lipoprotein cholesterol (LDL-C) who may not have found success with existing therapies.

Highlights of the Conferences

Company management is set to participate in several prestigious investor conferences, giving key stakeholders the opportunity to gain insights into their latest advancements. Here’s a brief overview of what’s to come:

William Blair 45th Annual Growth Stock Conference

Set to take place in Chicago, NewAmsterdam’s CEO, Michael Davidson, M.D., will present a corporate overview on Tuesday, June 3. Attendees can tune in at 3:20 p.m. CT to hear about the company's strategic vision and recent developments in their CVD-focused therapies.

Jefferies Global Healthcare Conference 2025

Following the William Blair event, NewAmsterdam will be at the Jefferies Global Healthcare Conference in New York on Wednesday, June 4. Chief Financial Officer, Ian Somaiya, is scheduled for an engaging fireside chat at 10:30 a.m. ET, where he will discuss the company's financial outlook and market position.

Goldman Sachs 46th Annual Healthcare Conference

Miami will be the location for the final event in this series, with Michael Davidson returning alongside Matthew Phillipe, Executive Vice President and Head of Investor Relations, for a fireside chat on Monday, June 9 at 2:40 p.m. ET. This discussion is anticipated to cover NewAmsterdam's innovative therapies and their potential impact on patients suffering from high LDL-C levels.

Live Webcasts and Access to Presentations

For those unable to attend in person, live webcasts of these vital presentations will be available through the investor relations section of the NewAmsterdam Pharma website. Post-event, archived replays will also be accessible, ensuring that stakeholders can stay informed about the company’s developments and insights shared during these conferences.

About NewAmsterdam Pharma

NewAmsterdam Pharma (Nasdaq: NAMS) stands at the forefront of biopharmaceutical innovation with a mission to enhance patient care within populations suffering from metabolic diseases. Their core focus is on delivering a safe and convenient LDL-lowering therapy. Their flagship product, obicetrapib, is currently under investigation in multiple phase 3 trials as a potent, oral therapy designed to complement statin treatments for patients with elevated LDL-C who are not responding to existing therapies.

Company Contact Information

For inquiries, the company is accessible as follows:

Matthew Philippe
P: 1-917-882-7512
Email: matthew.philippe@newamsterdampharma.com

Media Contact
Spectrum Science on behalf of NewAmsterdam
Jaryd Leady
P: 1-856-803-7855
Email: jleady@spectrumscience.com

Investor Contact
Precision AQ on behalf of NewAmsterdam
Austin Murtagh
P: 1-212-698-8696
Email: austin.murtagh@precisionaq.com

Frequently Asked Questions

What is NewAmsterdam Pharma known for?

NewAmsterdam Pharma specializes in developing innovative oral therapies for cardiovascular disease, particularly focusing on LDL-lowering treatments.

When are the upcoming investor conferences?

The conferences are scheduled for June 3, June 4, and June 9 of the upcoming month.

Who will represent the company at these conferences?

Key representatives include CEO Michael Davidson, M.D. and CFO Ian Somaiya, among other executives.

How can stakeholders access the conference presentations?

Live webcasts will be available via the NewAmsterdam Pharma investor relations website, with replays posted afterward.

What is the significance of obicetrapib?

Obicetrapib is a promising oral therapy under investigation that aims to provide a novel solution for lowering LDL-C in patients at risk for cardiovascular disease.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Wave Kids™ Unveils New Flavors for Kids' Drinks

Updated Category News Views 1

Sparking a Fresh Wave in the Kids' Beverage Market Alright, let me tell you about a new player plowing into the kids' drink scene. Wave Kids™, a brand that's making waves—pun intended—has a fresh lineup that screams 'fun' and 'healthy' in equal measure. Just coinciding with back-to-school season, this Scottsdale, Arizona outfit has rolled out not one or two, but...

Continue Reading
South Florida Donor Network Honors 52 Heroic Donors

Updated Category News Views 3

A Heartfelt Tribute to Lifesavers You ever been to a gathering that reminds you how deeply human connections run? That's what happened at The Diplomat Beach Resort in Hollywood. South Florida Donor Network (SFDN) pulled together a ceremony honoring 52 donor heroes whose legacies beat strong through the recipients living thanks to their gifts. An Event Worth Attending...

Continue Reading
ZEEKR's Shooting Brakes Dominate: Over 400K Sold

Updated Category News Views 2

ZEEKR's Stellar Performance in a Crowded Market Another month, another bumper crop for ZEEKR's shooting brakes. These beauties aren't just hanging in there; they're leading the pack. In August alone, global deliveries marched past the 10,000 mark for the third month running—a feat not easily achieved in today's saturated automotive landscape. It's no wonder the...

Continue Reading
Midlife ADHD in Women: New Challenges and Solutions

Updated Category News Views 0

ADHD Evolution in Women's Midlife They say change is the only constant, and boy, does that ring true for women navigating the turbulent seas of ADHD as they hit 40 and beyond. According to Germaine Swanson, the ADHD landscape changes dramatically in midlife, especially for women. We're talking about a mix of hormonal shifts, increasing life demands, and changes in brain...

Continue Reading
Tampa General’s Innovation Excellence Earns No. 20 Spot

Updated Category News Views 0

A Bold Leap into Innovation at Tampa General There's a heck of a lot going on down in Tampa that's worth more than just a golf clap. Tampa General Hospital (TGH) just snagged the 20th spot on Fast Company's Best Workplaces for Innovators list, and let me tell you, that’s no small feat amidst the heavy hitters in verticals like biotech and consumer goods. It takes guts...

Continue Reading
CUBEX Lights Up Veterinary Care with Mini Essential

Updated Category News Views 2

Inventory Woes? Meet Mini Essential If you’ve ever worked in or around veterinary hospitals, you know the old-school headaches of managing controlled substances. Picture this: piles of paper logs, end-of-shift recounting, and inevitable discrepancies that rear their ugly heads long after closing time. Enter CUBEX, shaking things up with their latest launch, Mini...

Continue Reading
LeoLabs and SciTec Partner for $93.7M Space Force Deal

Updated Category News Views 1

LeoLabs and SciTec Join Forces for Space Dominance The space race ain't just about rockets blasting off anymore. It's about making sure we've got eyes everywhere, even on the back of our heads, so to speak. Enter LeoLabs teaming up with SciTec to help the U.S. Space Force upgrade their radar systems to something out of a sci-fi flick, armed with a $93.7 million contract...

Continue Reading
RARE Foundation Rebrands, Focus Still Strong

Updated Category News Views 1

Unveiling the RARE Foundation's New Identity In the stock market, you ride waves of change, and let me tell you, it ain't just stocks and bonds that change names and faces. Case in point: The EveryLife Foundation for Rare Diseases has spiffed up as the RARE Foundation. New name, new logo, the whole enchilada. This isn't just a cosmetic touch-up, though. It's about...

Continue Reading
Woodpack Global Unveils Crate Design System: A New Era Begins

Updated Category News Views 0

Innovating the Wooden Crate Landscape An old industry got a much-needed facelift today, folks. Woodpack Global has rolled out Crate Design System™ (CDS)—a snazzy new tool that's shaking up the wooden crate design landscape. It blows the dust off outdated design methods that have been collecting cobwebs since the '60s. That's right, we’re talking about a significant...

Continue Reading
WNET's 25th Anniversary 9/11 Tribute: Stories and Lessons

Updated Category News Views 0

Reflecting on a Dark Day with WNET's Programming Nothing quite hits you like the anniversary of a colossal tragedy. The memories of September 11, 2001, remain etched in the urban landscape of New York City, and this year marks 25 years since that heart-wrenching day. The WNET Group steps up to the plate with a comprehensive slate of programming aimed at honoring the...

Continue Reading

Top 5 Most Recently Viewed Articles

Lateral Pharma Uncovers LanCL1's Role in Pain Relief

Updated Category News Views 2

Breaking New Ground in Neuropathic Pain Well, here's a slice of the biotech landscape changing in real-time, and it's not just hype this time around. Lateral Pharma is shaking up the world of neuropathic pain treatment with their fresh discovery published in the revered pages of PAIN. These folks from Melbourne think they've got something big with Lanthionine Synthetase...

Continue Reading
Shineco Inc (SISI) Faces Turbulent Times Amid Stock Struggles

Updated Category News Views 85

Shineco Inc Stock Struggles with 52-Week Low Shineco Inc (SISI) has experienced a concerning downturn as its stock reached a 52-week low of $0.2. This dramatic decline showcases a staggering 86.19% drop over the past year, raising concerns among investors and market analysts. As the company navigates through a tough period, the current stock price represents a crucial...

Continue Reading
Investors' Opportunity to Engage in Pacira BioSciences Lawsuit

Updated Category News Views 150

Investors' Opportunity to Engage in Pacira BioSciences Lawsuit Recent developments have created an opportunity for investors in Pacira BioSciences, Inc. (NASDAQ: PCRX) regarding potential securities fraud allegations. The Rosen Law Firm, known for safeguarding investor rights, is reminding those who purchased securities of Pacira during a specific time frame that they may...

Continue Reading
Euroseas Ltd. Achieves Strong Financial Performance in Q3 2025

Updated Category News Views 143

Overview of Q3 2025 Financial Results Euroseas Ltd. (NASDAQ: ESEA), an owner and operator of container carrier vessels, displayed remarkable performance for the third quarter of 2025, showcasing its operational resilience and strategic initiatives. The company reported total net revenues of $56.9 million, reflecting a solid increase compared to the same period from the...

Continue Reading
Key Insights on Advanced Medical Solutions Group Disclosure

Updated Category News Views 180

Understanding Disclosure Requirements for Securities In the realm of investment, particularly in publicly traded companies, disclosure of significant dealings in securities is pivotal. A recent disclosure pertains to Advanced Medical Solutions Group Plc, detailing interests of a person holding 1% or more of relevant securities. The purpose of this disclosure is to provide...

Continue Reading